These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 17221153)
21. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452 [TBL] [Abstract][Full Text] [Related]
22. The importance of prognostic factors in premenopausal women with breast cancer. Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790 [TBL] [Abstract][Full Text] [Related]
23. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy. Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O; Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568 [TBL] [Abstract][Full Text] [Related]
24. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412 [TBL] [Abstract][Full Text] [Related]
25. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731 [TBL] [Abstract][Full Text] [Related]
26. Increased expression of osteopontin in patients with triple-negative breast cancer. Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545 [TBL] [Abstract][Full Text] [Related]
27. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083 [TBL] [Abstract][Full Text] [Related]
28. Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target. Coyle YM; Xie XJ; Hardy DB; Ashfaq R; Mendelson CR Cancer Lett; 2007 Dec; 258(2):253-61. PubMed ID: 17950525 [TBL] [Abstract][Full Text] [Related]
29. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Di Saverio S; Gutierrez J; Avisar E Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874 [TBL] [Abstract][Full Text] [Related]
30. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556 [TBL] [Abstract][Full Text] [Related]
31. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635 [TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124 [TBL] [Abstract][Full Text] [Related]
33. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272 [TBL] [Abstract][Full Text] [Related]
34. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533 [TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Yu H; Giai M; Diamandis EP; Katsaros D; Sutherland DJ; Levesque MA; Roagna R; Ponzone R; Sismondi P Cancer Res; 1995 May; 55(10):2104-10. PubMed ID: 7538047 [TBL] [Abstract][Full Text] [Related]
36. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647 [TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553 [TBL] [Abstract][Full Text] [Related]
38. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942 [TBL] [Abstract][Full Text] [Related]
39. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334 [TBL] [Abstract][Full Text] [Related]
40. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]